arrow
P

Paulo Roberto Abrão Ferreira

Weill Cornell Medicine
H指数:21
被引数:5,074

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Virological and Immunological Outcomes of Combined Therapeutic Interventions and Dendritic Cell Therapy in People With HIV

HIV感染者中联合治疗干预和树突状细胞疗法的病毒学和免疫学结局

2025-08-010
OAAI
Adjusted estimate of the prevalence of hepatitis delta virus in 25 countries and territories

25个国家和地区丁型肝炎病毒流行率的调整估计

2024-02-0125
OAAI
Hepatitis D double reflex testing of all hepatitis B carriers in low-HBV- and high-HBV/HDV-prevalence countries

在低HBV和高HBV/HDV流行国家中所有乙型肝炎携带者的丁型肝炎双反射检测

2023-08-0127
OAAI
A Machine Learning Model for Predicting Hospitalization in Patients with Respiratory Symptoms during the COVID-19 Pandemic

预测新型冠状病毒肺炎大流行期间呼吸道症状患者住院的机器学习模型

2022-08-057
OAAI
National Brazilian survey on the outcomes of hepatitis c retreatment in patients non-responders to direct antiviral agents
2022-07-013
OA
Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study

丙型肝炎病毒患病率的全球变化以及护理2015年和2020的级联: 一项建模研究

2022-05-01368
OAAI
Impact of In-Hospital infection with SARS-CoV-2 among Inpatients at a university hospital
2021-12-016
OAAI
Brazilian Society of Hepatology and Brazilian Society of Infectious Diseases Guidelines for the Diagnosis and Treatment of Hepatitis B
2020-09-0111
OAAI
Hepatitis C disease burden and strategies for elimination by 2030 in Brazil. A mathematical modeling approach
2019-05-0140
OAAI
Histoplasmosis, An Underdiagnosed Disease Affecting People Living With HIV/AIDS in Brazil: Results of a Multicenter Prospective Cohort Study Using Both Classical Mycology Tests and Histoplasma Urine Antigen Detection
2019-04-1378
OAAI
Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir ± Ribavirin for HCV in Brazilian Adults with Advanced Fibrosis
2018-07-314
OA
Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study
2017-03-011.5K
OAAI